subscribeSubscribe
Secura Bio to keep offering blood cancer drug despite negative ODAC vote

Secura Bio to keep offering blood cancer drug despite negative ODAC vote
Zachary Brennan ENDPTS
23 Mar 2023
Share Share
Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib

Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib
PR NEWSWIRE
09 Jan 2023
Share Share
FDA threatens to clamp down on another PI3K blood cancer drug—a full approval

FDA threatens to clamp down on another PI3K blood cancer drug—a full approval
Angus Liu FIERCEPHARMA
23 Sep 2022
Share Share
FDA Warns of Increased Mortality Risk With Duvelisib

FDA Warns of Increased Mortality Risk With Duvelisib
Mike Bassett MEDPAGETODAY
01 Jul 2022
Share Share
PI3K inhibitor hit with an increased death risk warning from FDA

PI3K inhibitor hit with an increased death risk warning from FDA
Zachary Brennan ENDPTS
01 Jul 2022
Share Share
SECURA BIO ANNOUNCES PRESENTATION OF COPIKTRA DATA FOR PTCL

SECURA BIO ANNOUNCES PRESENTATION OF COPIKTRA DATA FOR PTCL
PRNEWSWIRE
14 Dec 2021
Share Share
Secura Bio Announces Copiktra (duvelisib) Strategic Focus On T-cell Lymphoma

Secura Bio Announces Copiktra (duvelisib) Strategic Focus On T-cell Lymphoma
PRNEWSWIRE
03 Dec 2021
Share Share
COPIKTRA® (duvelisib) Receives EMA for the Treatment

COPIKTRA® (duvelisib) Receives EMA for the Treatment
PRNEWSWIRE
09 Jun 2021
Share Share
Secura Bio Announces Enrollment Completion of the COPIKTRA®

Secura Bio Announces Enrollment Completion of the COPIKTRA®
PRNEWSWIRE
08 Apr 2021
Share Share
COPIKTRA® (duvelisib) Receives Positive CHMP Opinion for the Treatment

COPIKTRA® (duvelisib) Receives Positive CHMP Opinion for the Treatment
PRNEWSWIRE
01 Apr 2021
Share Share